European Medicines Agency grants aspacytarabine orphan drug designation for the treatment of acute myeloid leukaemia
Aspacytarabine is composed of cytarabine covalently bound to asparagine. Due to its unique pharmacokinetics and metabolism, aspacytarabine enables high-dose therapy with lower systemic exposure to free cytarabine and relative sparing of normal tissues. A Phase 2b study is ongoing
Source:
Biospace Inc.